T Hercend
Overview
Explore the profile of T Hercend including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
3454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico J, et al.
Eur Cytokine Netw
. 2000 Mar;
11(1):91-8.
PMID: 10705305
Immunological control of acute leukemia may be achieved after allogeneic transplant. Despite promising preliminary results, the impact of immunotherapy with interleukin-2 (r-IL-2) on patients with acute leukemia (AL), in first...
2.
Vey N, Blaise D, Lafage M, Olive D, Viens P, Baume D, et al.
J Immunother
. 1999 Mar;
22(2):175-81.
PMID: 10093042
We designed a phase II study to assess the activity of recombinant interleukin-2 (rIL-2) in patients with chronic myelogenous leukemia (CML). Study population included 11 patients in the chronic phase...
3.
Zorn E, Hercend T
Eur J Immunol
. 1999 Mar;
29(2):602-7.
PMID: 10064076
In recent years, experiments based on the in vitro stimulation of either autologous peripheral blood lymphocytes or tumor-infiltrating lymphocytes with melanoma cells have shown that distinct members of the large...
4.
Zorn E, Hercend T
Eur J Immunol
. 1999 Mar;
29(2):592-601.
PMID: 10064075
We have studied a case of human primary melanoma displaying the classical signs of a spontaneous regression in order to characterize potentially efficient anti-tumor T cell responses. In a previous...
5.
Maraninchi D, Vey N, Viens P, Stoppa A, Archimbaud E, Attal M, et al.
Leuk Lymphoma
. 1998 Dec;
31(3-4):343-9.
PMID: 9869198
In this report we present the results of a multicenter phase II study of high-dose recombinant Interleukin-2 (rIL-2) in patients with refractory or relapsed acute leukemia. Forty-nine patients with acute...
6.
Angevin E, Kremer F, Gaudin C, Hercend T, Triebel F
Int J Cancer
. 1997 Jul;
72(3):431-40.
PMID: 9247286
We assessed the naturally occurring T-cell immune response in primary renal cell carcinoma (RCC) tumors from 12 unselected patients. A predominance of CD3+ T-cell receptor (TCR)alpha/beta+ T cells was observed...
7.
Carcelain G, Rouas-Freiss N, Zorn E, Viel S, Faure F, Bosq J, et al.
Int J Cancer
. 1997 Jul;
72(2):241-7.
PMID: 9219827
In an earlier study of the immune response in a patient with a cutaneous primary regressive melanoma, a T-cell-receptor diversity analysis demonstrated in situ amplification of certain lymphocytes. Two of...
8.
Housseau F, Zeliszewski D, Roy M, Paradis V, Richon S, Ricour A, et al.
Int J Cancer
. 1997 May;
71(4):585-94.
PMID: 9178812
Tumor-infiltrating lymphocytes (TIL) were grown from 23 urothelial carcinomas. Phenotyping analysis showed that the TIL cultures were mainly CD3+. Although CD4+ and CD8+ T-cell sub-sets were grown in culture, CD4+...
9.
Blaise D, Attal M, Pico J, Reiffers J, Stoppa A, Bellanger C, et al.
Leuk Lymphoma
. 1997 May;
25(5-6):469-78.
PMID: 9250817
We report the outcome of 50 consecutive patients with CR1 acute leukemia (AML = 22; ALL = 28) treated with autologous BMT, after cyclophosphamide and TBI, followed with a sequential...
10.
Williamson R, Yea C, Robson P, Curnock A, Gadher S, Hambleton A, et al.
Transplant Proc
. 1996 Dec;
28(6):3088-91.
PMID: 8962196
No abstract available.